(FM) Oncología
Departamento académico
Javier
Cortés Castán
Publikationen, an denen er mitarbeitet Javier Cortés Castán (27)
2023
2022
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530
2019
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
-
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors
Melanoma Research, Vol. 25, Núm. 6, pp. 486-495
2012
-
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis
Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137
-
Progress against solid tumors in danger: The metastatic breast cancer example
Journal of Clinical Oncology
2006
-
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation
International Journal of Radiation Oncology Biology Physics, Vol. 64, Núm. 4, pp. 1122-1128
2005
-
Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer
International Journal of Radiation Oncology Biology Physics, Vol. 61, Núm. 5, pp. 1378-1384
-
Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?
World Journal of Gastroenterology
2004
-
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, Núm. 3, pp. 299-303
2003
-
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
Oncology, Vol. 64, Núm. 1, pp. 28-35
-
[18F]-FDG PET and localized fibrous mesothelioma
Lung, Vol. 181, Núm. 1, pp. 49-54